Dendritic cells transduced with Rsf-1/HBXAP gene generate specific cytotoxic T lymphocytes against ovarian cancer in vitro

Biochemical and Biophysical Research Communications

Volumn 394, Issue 3, 2010, Pages 633-638

  Sun, Li ^a,b   Kong, Beihua ^b   Sheng, Xiugui ^a   Sheu, Jim Jinn Chyuan ^c   Shih, Ie Ming ^d  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b SHANDONG UNIVERSITY   (China)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d Oncology   (United States)

Author keywords

Cytotoxic T lymphocyte; Dendritic cell; Immunotherapy; Ovarian cancer; Rsf 1 HBXAP

Indexed keywords

CELL PROTEIN; HEPATITIS B VIRUS X PROTEIN; PLASMID DNA; REMODELING AND SPACING FACTOR 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOLOGY; CANCER INHIBITION; CD34 SELECTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; OVARY CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UMBILICAL CORD BLOOD;

CANCER VACCINES; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TRANS-ACTIVATORS; TRANSDUCTION, GENETIC;

EID: 77950517565     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.03.038     Document Type: Article

References (26)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J. Clin. 57 (2007) 43-66
2. Kinzler K.W., and Vogelstein B. The Genetic Basis of Human Cancer. second ed. (2002), McGraw-Hill, Toronto
3. Shih Ie M., Sheu J.J., Santillan A., et al. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc. Natl. Acad. Sci. USA 102 (2005) 14004-14009
4. Mao T.L., Hsu C.Y., Yen M.J., et al. Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma. Hum. Pathol. 37 (2006) 1169-1175
5. Davidson B., Trope' C.G., Wang T.L., et al. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival. Gynecol. Oncol. 103 3 (2006) 814-819
6. Choi J.H., Sheu J.J.-C., Guan B., et al. Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian Cancer. Cancer Res. 69 4 (2009) 1407-1415
7. Steinman R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9 (1991) 271-296
8. Tuting T., Wilson C.C., Martin D.M., et al. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. J. Immunol. 160 3 (1998) 1139-1147
9. Celluzzi C.M., and Falo Jr. L.D. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J. Immunol. 160 7 (1998) 3081-3085
10. Song W., Kong H.L., Carpenter H., et al. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 186 8 (1997) 1247-1256
11. Diebold S.S., Cotton M., Koch N., et al. MHC class II presentation of endogenously expressed antigens by transfected dendritic cells. Gene Ther. 8 6 (2001) 487-493
12. Kaplan J.M., Yu Q., Piraino S.T., et al. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J. Immunol. 163 2 (1999) 699-707
13. Salio M., Dulphy N., Renneson J., et al. Efficient priming of antigen-specific cytotoxic T lymphocytes by human cord blood dendritic cells. Int. Immunol. 15 10 (2003) 1265-1273
14. Korokhov N., de Gruijl T.D., Aldrich W.A., et al. High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN. Cancer Biol. Ther. 4 3 (2005) 289-294
15. Lenz P., Bacot S.M., Frazier-Jessen M.R., et al. Nucleoporation of dendritic cells: efficient gene transfer by electroporation into human monocyte-derived dendritic cells. FEBS Lett. 538 1-3 (2003) 149-154
16. Luft T., Jefford M., Luetjens P., et al. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets. Blood 100 4 (2002) 1362-1372
17. Yamanaka R., Zullo S.A., Tanaka R., et al. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. J. Neurosurg. 94 3 (2001) 474-481
18. Ribas A., Butterfield L.H., Glaspy J.A., et al. Cancer immunotherapy using gene-modified dendritic cells. Curr. Gene Ther. 2 1 (2002) 57-78
19. Lotem M., Zhao Y., Riley J., et al. Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors. J. Immunother. 29 6 (2006) 616-627
20. Temme A., Morgenroth A., Schmitz M., et al. Efficient transduction and long-term retroviral expression of the melanoma-associated tumor antigen tyrosinase in CD34+ cord blood-derived dendritic cells. Gene Ther. 9 22 (2002) 1551-1560
21. Oki M., Ando K., Hagihara M., et al. Efficient lentiviral transduction of human cord blood CD34+ cells followed by their expansion and differentiation into dendritic cells. Exp. Hematol. 29 10 (2001) 1210-1217
22. Lohmann S., Galle K., Knop J., et al. CD83+ human dendritic cells transfected with tumor peptide cDNA by electroporation induce specific T-cell responses: a potential tool for gene immunotherapy. Cancer Gene Ther. 7 4 (2000) 605-614
23. Van Tendeloo V.F., Snoeck H.W., Lardon F., et al. Nonviral transfection of distinct types of human dendritic cells: high-efficiency gene transfer by electroporation into hematopoietic progenitor - but not monocyte-derived dendritic cells. Gene Ther. 5 5 (1998) 700-707
24. Steinman R.M., and Banchereau J. Taking dendritic cells into medicine. Nature 449 7161 (2007) 419-426
25. Dredge K., Marriott J.B., Todryk S.M., et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J. Immunol. 168 10 (2002) 4914-4919
26. Pletneva M., Fan H., Park J.J., et al. IFN-producing killer dendritic cells are antigen-presenting cells endowed with T-cell cross-priming capacity. Cancer Res. 69 16 (2009) 6607-6614